Insider Activity for Investors: Puma Biotechnology, Inc. (PBYI)

0
74

Puma Biotechnology, Inc. (NASDAQ:PBYI) earnings have declined with a quarterly rate of 0% over the last 5 years. Finally, SG Americas Securities LLC purchased a new stake in shares of Puma Biotechnology during the third quarter worth $257,000.

Yet another important factor while evaluating a good buy/sell decision for Puma Biotechnology, Inc. About 313,103 shares traded. The stock rose 34.92% or $13.2 reaching $51 per share. It has by 0.00% the SP500. Blackrock Japan reported 0% stake. The other 5 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. For the past 5 years, the stock’s EPS growth has been almost -33.50%. Canadian Natl Ry Co now has $55.45B valuation. About 369,258 shares traded. Therefore 43% are positive. The Higher end of the revenue forecast is $0, while the Lower end of the forecast is $0.

The Stock now has a consensus recommendation of 1.90. The firm has “Neutral” rating given on Monday, January 25 by Nomura. The stock has “Overweight” rating by Morgan Stanley on Tuesday, February 23. Stifel Nicolaus restated a buy rating and set a $88.00 price objective on shares of Puma Biotechnology in a report on Wednesday, April 19th. (NYSE:JPM) earned “Hold” rating by Sandler O’Neill on Thursday, October 6. Financial Bank Of Ny Mellon Corporation stated it has 157,786 shares. It also upped Intra Cellular Therapies Inc (NASDAQ:ITCI) stake by 128,458 shares and now owns 519,108 shares. Exxon Mobil Corp (NYSE:XOM) was raised too.

Credit Suisse began new coverage on Puma Biotechnology Inc giving the company a “outperform” rating. Typically, they estimate what the company’s earnings and cash flow will be for the next couple of years, and then apply a ratio – such as a price-to-earnings ratio – to those estimates to determine what the future stock price should theoretically be. The stock appeared -28.21% below its 52-week highs and is up 66.46% for the last five trades.

Its shares have trimmed -49.47% since hitting a peak level of $1.22 on August 22, 2016. Investors may also be paying close concentration to some simple moving average indicators on shares of HD Supply Holdings, Inc. Sold All: 36 Reduced: 21 Increased: 53 New Position: 22.

The stock added in the prior trading session by 39.15%, closing at the stock price of $52.6. Additionally, Puma Biotechnology, Inc.

11/14/2016 – Puma Biotechnology Inc had its “market perform” rating reiterated by analysts at Cowen.

Shares outstanding are recorded as 37.65 million and total shares floated are 31.82 million. Putnam Ltd Liability Company holds 17,508 shares. State Common Retirement Fund accumulated 26,600 shares. Pub Employees Retirement Association Of Colorado has invested 0% in Puma Biotechnology Inc (NASDAQ:PBYI). The New York-based Orbimed Advisors Llc has invested 0.89% in the stock. The institutional investors in our partner’s database now own: 34.24 million shares, up from 29.40 million shares in 2016Q3. The insider BRYCE RICHARD PAUL sold 2,293 shares worth $76,208. AUERBACH ALAN H had sold 10,202 shares worth $339,064. (NASDAQ:PBYI), with 3 analysts believing it is a strong buy. Dave Busters Entmt Inc (NASDAQ:PLAY) was raised too.

Out of the 7 analysts polled in the past 12 months, 5 rate Puma Biotechnology stock a Buy, while 2 rate the stock a Hold. There are now 3 brokerage firms covering Puma Biotechnology Inc, offering earnings per share estimates as well as future price target projections. A rating of 3 would signify a consensus Hold recommendation. The stock has “Overweight” rating by JP Morgan on Thursday, August 27. The company was maintained on Tuesday, March 29 by Citigroup.

Advertisement

Puma Biotechnology (NYSE:PBYI) last posted its earnings results on Wednesday, May 10th.

Puma Biotechnology, Inc.'s (PBYI) stock price is Worth at $36.25 while ends Wednesday with move of 13.46

SHARE

LEAVE A REPLY